Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab
Dan Turner(Shaare Zedek Medical Center), Jeffrey S. Hyams(Connecticut Children's Medical Center), Lakshmi Damaraju(Janssen (Belgium)), Anne M. Griffiths(University of Toronto), Jewel Johanns(Johnson & Johnson (United States)), Marion Blank(Janssen (United States)), Gigi Veerman(Statistics Belgium)
Cited by 67
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k